Treatment was also associated with reduced hepatic levels of WHV DNA replicative intermediate
(RI) (up to 41%), WHV covalently-closed circular (ccc) DNA (up to 32%), and WHV RNA (up to 50%), lower hepatic expression of WHV core and surface antigens, and reduced liver disease progression.
HCV RNA-negative strand is a replicative intermediate
in the viral life cycle and is generally accepted as evidence of ongoing HCV replication (Hepatology 2005;41:106-14).
In mouse models of HBV infection, a single injection of ARC-520 containing NAG-polymer and chol-siRNAs targeting conserved regions of the HBV transcripts resulted in multi-log reductions in circulating viral antigens and HBV DNA, and dramatically reduced HBV RNA and DNA replicative intermediates
in the liver.